Skip to main navigation
Quantum Si logo
  • Technology
  • Products
  • Applications
    • Antibody Characterization
    • Biomarker Identification
    • Protein Identification
    • Protein Variant
    • PTM Analysis
  • Resources
  • Investors
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • About Us
    • Careers
    • Leadership
  • Contact Us
Select Page
Quantum-Si Incorporated logo
    • Technology
    • Products
    • Applications
      • Antibody Characterization
      • Biomarker Identification
      • Protein Identification
      • Protein Variant
      • PTM Analysis
    • Resources
    • Investors
      • Press Releases
      • Events and Presentations
      • Stock Information
      • Financials
      • Governance
      • Investor Resources
    • About Us
      • Careers
      • Leadership
    • Contact Us

News Details

  • Overview
  • Press Releases
  • Events & Presentations
    Events Presentations
  • Stock Information
    Stock Quote & Chart Analyst Coverage Historic Price Lookup
  • Financials
    Quarterly Results Annual Reports SEC Filings
  • Governance
    Governance Highlights Leadership Board of Directors Committee Composition
  • Investor Resources
    Investor FAQs Investor Email Alerts Investor Contact

Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 15, 2026
PDF Version

BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1). Nasdaq determined that the closing bid price of the Company’s common stock had been at or above $1.00 per share for at least 10 consecutive business days. Accordingly, Nasdaq has advised the Company that the matter is closed.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

CONTACTS

Investor and Media
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com


Primary Logo

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact IR
Quantum-Si Incorporated logo
© Copyright 2026 QuantumSi | All rights reserved.
Follow us
  • LinkedIn
  • Twitter
  • Youtube
  • Instagram
  • Facebook